Barclays’s HCW Biologics HCWB Stock Holding History

Barclays’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$953	Buy	+191	New	+$1.08K	﹤0.01%	4934

Other funds holding HCWB

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Barclays's HCWB Position: Q2 2026 in Review

Barclays opened a new position in HCW Biologics (HCWB) in Q2 2026: 191 shares worth $953. The stake represents ﹤0.01% of the portfolio and ranks #4934 among its holdings.

12 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

Barclays held 191 shares of HCW Biologics worth $953 as of Q2 2026.
HCW Biologics was a new Barclays position in Q2 2026.
HCW Biologics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4934 holding.
12 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.